We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > MPM

News List

MHRA approves Opdivo plus Yervoy for unresectable malignant pleural mesothelioma pharmatimes
August 06, 2021
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bristol Myers Squibb's (BMS) Opdivo (nivolumab) plus Yervoy (ipilimumab) combination for the first-line treatment of adult patients with unresectable malignant pleural ...
EC Approval for Opdivo Plus Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma americanpharmaceuticalreview
June 04, 2021
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM).
3SBIO makes investment in MPM's $100M Oncology Innovations Fund and donation to Dana-Farber cancer research prnasia
March 01, 2020
The collaboration of INV and IRF is a unique, first of its kind, impact investing collaboration.